Journo leaders in the UK warn on old regulations for new healthcare AI

The Financial Times of London is calling for caution—along with standardized and modernized regulation—around AI in healthcare.

In a brief editorial published online June 21, the influential newspaper’s editorial board acknowledges several worthwhile innovations AI is bringing to Britain’s healthcare system. However, the team warns, more oversight is needed lest the technology “prove more of a liability than an asset.”

“There are clear advantages to tireless automated assistants and researchers capable of sorting through vast piles of data,” they write. “Yet there is a danger that the new technology falls into a regulatory grey area. The lack of a single bar risks companies applying various standards to products which directly affect the public.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup